Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

Introduction: This study evaluated the cost-effectiveness of abemaciclib plus fulvestrant (ABE + FUL) vs. palbociclib plus fulvestrant (PAL + FUL), ribociclib plus fulvestrant (RIB + FUL) and fulvestrant monotherapy (FUL) as second-line treatment for hormone receptor-positive and human epidermal gro...

Full description

Bibliographic Details
Main Authors: Yingcheng Wang, Mingjun Rui, Xin Guan, Yingdan Cao, Pingyu Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Medicine
Subjects:
cost-effectiveness
abemaciclib
CDK4/6 inhibitors
partitioned survival model
breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.658747/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.658747/full

Similar Items